Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 11—November 2011

CME ACTIVITY

Global Distribution and Epidemiologic Associations of Escherichia coli Clonal Group A, 1998–2007

James R. JohnsonComments to Author , Megan E. Menard, Tsai-Ling Lauderdale, Chris Kosmidis, David Gordon, Peter Collignon, Joel N. Maslow, Arjana Tambić Andrašević, and Michael A. Kuskowski
Author affiliations: Veterans Affairs Medical Center, Minneapolis, Minnesota, USA (J.R. Johnson, M.E. Menard, M.A. Kuskowski); University of Minnesota, Minneapolis (J.R. Johnson, M.A. Kuskowski); National Health Research Institutes, Zhunan, Taiwan (T.-L. Lauderdale); University of Athens Medical School, Athens, Greece (C. Kosmidis); Australian National University, Canberra, Australian Capital Territory, Australia (D. Gordon, P. Collignon); Canberra Hospital, Canberra (P. Collignon); Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA (J.N. Maslow); University of Pennsylvania, Philadelphia (J.N. Maslow); University Hospital for Infectious Diseases, Zagreb, Croatia (A. Tambić Andrašević)

Main Article

Table 3

Prevalence of clonal group A, by region and TMP/SMZ phenotype, among 2,210 extraintestinal Escherichia coli isolates from 32 globally distributed centers, 1998–2007*

Region No. clonal group A isolates/total no. (%) p value†
Total TMP/SMZ susceptible TMP/SMZ resistant
Overall 144/2,210 (6.5) 30/1,083 (2.8) 114/1,127 (10.1) <0.001
Africa 3/92 (3.3) 0/21 (0) 3/71 (4.2)
Asia 18/476 (3.8) 8/225 (3.6) 10/251 (4.0)
Australia/New Zealand 14/172 (8.1) 3/88 (3.4) 11/84 (13.1) 0.025
Europe 30/398 (7.5) 4/198 (2.0) 26/200 (13.0) <0.001
North America 63/858 (7.3) 12/471 (2.5) 51/387 (13.2) <0.001
South/Central America 16/214 (7.5) 3/80 (3.8) 13/134 (9.7)
Africa/Asia combined 21/568 (3.7) 8/246 (3.3)‡ 13/322 (4.0)§
Not Africa/Asia 123/1,642 (7.5) 22/837 (2.6)‡ 101/805 (12.5)§ <0.001

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†p values, by Fisher exact test, for TMP/SMZ-susceptible vs. -resistant isolates are shown where p<0.05; otherwise, p>0.10.
‡For Africa/Asia vs. other, p>0.10.
§For Africa/Asia vs. other, p<0.001.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†p values, by Fisher exact test, for TMP/SMZ-susceptible vs. -resistant isolates are shown where p<0.05; otherwise, p>0.10.
‡For Africa/Asia vs. other, p>0.10.
§For Africa/Asia vs. other, p<0.001.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†p values, by Fisher exact test, for TMP/SMZ-susceptible vs. -resistant isolates are shown where p<0.05; otherwise, p>0.10.
‡For Africa/Asia vs. other, p>0.10.
§For Africa/Asia vs. other, p<0.001.

Main Article

1Investigators who contributed data are listed at the end of this article.

TOP